

# PULMONARY FUNCTION TESTING: FOUNDATIONS & UPDATES

CAROLINE SISSON, MMS, PA-C  
ASSISTANT PROFESSOR



**Wake Forest University**  
**School of Medicine**



The academic core of



**Atrium Health**

# DISCLOSURES

I have no relevant relationships with ineligible companies to disclose within the past 24 months.

# OBJECTIVES

At the conclusion of this session, participants should be able to:

1. Use flow volume loop to differentiate restrictive pulmonary disease, obstructive pulmonary disease, variable extrathoracic obstruction, and fixed airway obstruction.
2. Interpret pulmonary function tests (spirometry, lung volumes, and diffusing capacity) as normal, restrictive, obstructive, or mixed.
3. Summarize 2021 European Respiratory Society/American Thoracic Society guidelines for interpreting pulmonary function testing using z-scores.

# COMPONENTS OF PULMONARY FUNCTION TESTS

## Spirometry

- How much air is moving?
- How fast is it moving?



## DLCO

- How well does air move from alveoli to capillaries?



## Lung Volumes

- How much air do the lungs hold?



**Can they do the test???**

# PFT=PULMONARY FUNCTION TESTS

## **Indications**

Diagnosis

Monitoring

Disability/impairment evaluation

## **Contraindications**

Increased myocardial demand

Increased pressure:

- Blood Pressure
- Intracranial
- Intraocular
- Sinus/middle ear
- Intrathoracic
- Intra-abdominal


Active infection




# SPIROMETRY

LUNG VOLUMES  
DIFFUSING CAPACITY

---





# HOW MUCH AIR IS MOVING? VOLUME

Forced Vital Capacity

**MAXIMUM  
CAPACITY**





# HOW FAST IS IT MOVING? FLOW

Forced Expiratory Volume in 1 second  
(FEV<sub>1</sub>)

- Volume expired in first second


FEV<sub>1</sub>/FVC

- Portion of FVC that is expelled in 1 second
- Reduced value indicates obstruction, a “straw” problem



**“America is all about speed.  
Hot, nasty, bad speed!”**

**Eleanor Roosevelt, 1936**



obstructive

- Narrowing of airways that results in reduction of maximal airflow in relation to maximal volume


restrictive

- Disease of lung, chest wall, pleural space, or NM that reduce *lung volumes*



combined

- Reduced lung volumes, vital capacity and airflow with airway narrowing



## CATEGORIES OF ABNORMAL FINDINGS

**2**



# EXAMPLES



# EXAMPLES



# EXAMPLES



WHAT IS  
NORMAL  
ANYWAY?

## FVC and FEV<sub>1</sub>

- $\geq 80\%$  *predicted*
- $> \text{LLN}$

## FEV<sub>1</sub>/FVC

- $\geq 70\%$
- $> \text{LLN}$



OUT WITH THE  
OLD...





Figure 4. FEV<sub>1</sub>/FVC predicted and limits of normal compared with the fixed cut-off of 0.7



ERS



ATS American Thoracic Society






ERS




**ATS** American  
Thoracic  
Society



# PUT IT TOGETHER


	FEV <sub>1</sub>	FVC	FEV <sub>1</sub> /FVC Ratio
Obstructive Disease	Normal or Decreased	Normal or Decreased	<b>Decreased?</b>
Restrictive Disease	Normal or Decreased	<b>Decreased</b>	<b>Normal</b>




FEV1 z-score	Impairment Severity
1.65 to -2.5	Mild
-2.5 to -4.0	Moderate
Less than -4.0	Severe

FEV1 % pred	Impairment Severity
>70%	Mild
50-70%	Moderate
35-50%	Severe
<35%	Very Severe


FEV<sub>1</sub> determines severity of obstruction








# LUNG VOLUMES & CAPACITIES




Source: M. A. Grippi, D. E. Antin-Ozerkis, C. S. Dela Cruz, R. M. Kotloff, C. N. Kotton, A. I. Pack: Fishman's Pulmonary Diseases and Disorders, 6e Copyright © McGraw Hill Education. All rights reserved.


# OBSTRUCTION WITH “NORMAL” FEV<sub>1</sub>/FVC



Source: M. A. Grippi, D. E. Antin-Ozerkis, C. S. Dela Cruz, R. M. Kotloff, C. N. Kotton, A. I. Pack: Fishman's Pulmonary Diseases and Disorders, 6e Copyright © McGraw Hill Education. All rights reserved.



# LUNG VOLUMES CONFIRM RESTRICTION AND/OR MIXED



Source: M. A. Grippi, D. E. Antin-Ozerkis, C. S. Dela Cruz, R. M. Kotloff, C. N. Kotton, A. I. Pack: Fishman's Pulmonary Diseases and Disorders, 6e Copyright © McGraw Hill Education. All rights reserved.




SPIROMETRY  
LUNG VOLUMES  
DIFFUSING CAPACITY

---



# DLCO: HOW DO WE DO IT?



**Step 1:** Inspire full breath of CO (measured)

**Step 2:** Hold breath x 10 seconds

**Step 3:** Exhale Maximally (measure amount of CO)

**Step 4:** Measure difference in inspired and expired CO to determine how much CO crossed into the blood stream

# DLCO: VARIABLES ASSESSED

## **Alveolar Surface Area**

How much area is available to allow for diffusion?

## **Pulmonary Perfusion**

How much blood (and Hgb) is available to take up the CO?

# DLCO: PUT IT TOGETHER

<b>Low</b>	<b>Normal</b>	<b>High</b>
Reduced diffusion due to alveolar disease	Extrinsic restrictive disease	Increased pulmonary perfusion
Decreased perfusion (i.e. narrowed or sclerosed arteries, thromboembolism)		High RBC
Anemia		



## DLCO: CLINICAL APPLICATION

Asthma &  
Chronic  
Bronchitis

• Normal DLCO

Emphysema

• Low DLCO

## DLCO: CLINICAL APPLICATION


Disorders of  
chest wall or  
NM disease

- Normal DLCO

Pulmonary  
Parenchymal  
Disease

- Low DLCO

# DLCO CAN LOCALIZE PATHOLOGY



Source: M. A. Grippi, D. E. Antin-Ozerkis, C. S. Dela Cruz, R. M. Kotloff, C. N. Kotton, A. I. Pack: Fishman's Pulmonary Diseases and Disorders, 6e Copyright © McGraw Hill Education. All rights reserved.




# BRONCHODILATOR RESPONSE

---



# BRONCHODILATOR RESPONSE



# BRONCHODILATOR RESPONSE (BDR)

## OLD

>200 mL AND  $\geq 12\%$  in FEV<sub>1</sub> and/or FVC

Change assessed on absolute and relative changes from *initial* values

Limitation: inversely proportional to baseline lung function

## NEW

Change assessed based on individual's *predicted* value

>10% relative to predicted value for FEV<sub>1</sub> or FVC

Advantage: avoids misinterpretation due to magnitude of baseline lung dysfunction

# BRONCHODILATOR RESPONSE (BDR): AN EXAMPLE

$\frac{(\text{Post BD value}) - (\text{Pre BD value})}{\text{Predicted value}}$

Predicted value

Pre-BD FEV<sub>1</sub> = 2.0L

Post-BD FEV<sub>1</sub> = 2.4L

Predicted FEV<sub>1</sub> = 3.32L

>10% relative to predicted value for FEV<sub>1</sub> or FVC

How should these results be interpreted?

- A. Significant Response to Bronchodilator
- B. No Significant Response to Bronchodilator

# INDICATIONS FOR SERIAL PULMONARY FUNCTION TESTING



Track Course of Disease



Response to Treatment



**SIGNIFICANT  
CHANGE**

15% change in  
FVC or FEV<sub>1</sub>

10% change in  
DLCO

**DISCLAIMER**

# REFERENCES

Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. *Eur Respir J* 2022; 60: 2101499 [DOI: 10.1183/13993003.01499-2021].

*Global Initiative for Chronic Obstructive Lung Disease (2024). Global Strategy for Prevention, Diagnosis, and Management of COPD: 2024 Report.*

*Global Initiative for Asthma (2023). Global Strategy for Asthma Management and Prevention.*

Grippi MA, Tino G. Pulmonary Function Testing. In: Grippi MA, Antin-Ozerkis DE, Dela Cruz CS, Kotloff RM, Kotton C, Pack AI. eds. *Fishman's Pulmonary Diseases and Disorders, 6e*. McGraw-Hill Education; 2023.



# QUESTIONS

---

[CABELL@WAKEHEALTH.EDU](mailto:CABELL@WAKEHEALTH.EDU)